258 related articles for article (PubMed ID: 34417989)
21. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
22. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.
Chen HD; Zhou J; Wen F; Zhang PF; Zhou KX; Zheng HR; Yang Y; Li Q
J Cancer Res Clin Oncol; 2017 Feb; 143(2):361-368. PubMed ID: 27798730
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
Liu G; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
Lin J; Fang Q; Zheng X
PLoS One; 2023; 18(2):e0281402. PubMed ID: 36749752
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
Wu D; Nie J; Hu W; Dai L; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Int J Cancer; 2020 Dec; 147(12):3453-3460. PubMed ID: 32557583
[TBL] [Abstract][Full Text] [Related]
27. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
28. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
30. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.
Shu Y; Zhang Q; He X; Chen L
Cancer Manag Res; 2021; 13():8297-8306. PubMed ID: 34764692
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Liao W; Huang J; Hutton D; Li Q
J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
[TBL] [Abstract][Full Text] [Related]
33. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
34. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
Front Public Health; 2022; 10():942800. PubMed ID: 35923949
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
[TBL] [Abstract][Full Text] [Related]
36. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
Zeng X; Li J; Peng L; Wang Y; Tan C; Chen G; Wan X; Lu Q; Yi L
PLoS One; 2014; 9(2):e88881. PubMed ID: 24586426
[TBL] [Abstract][Full Text] [Related]
37. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.
Zhang C; Wang J; Wang X; Meng Z; Cheng Y; Li K
Cancer Biol Med; 2021 Jul; 19(8):1249-58. PubMed ID: 34302324
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
Wu Y; Zhang T; Liu Y; Wang J; Bi N
Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
Qiu Y; Zha J; Ma A; Zhou T
Gynecol Oncol; 2023 Jul; 174():175-181. PubMed ID: 37209503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
